An Fc-muted bispecific antibody targeting PD-L1 and 4-1BB induces antitumor immune activity in colorectal cancer without systemic toxicity

被引：0
|
作者：
Lian-sheng Cheng
Min Zhu
Yan Gao
Wen-ting Liu
Wu Yin
Pengfei Zhou
Zhongliang Zhu
Liwen Niu
Xiaoli Zeng
Dayan Zhang
Qing Fang
Fengrong Wang
Qun Zhao
Yan Zhang
Guodong Shen
机构：
[1] University of Science and Technology of China,Department of Geriatrics, The First Affiliated Hospital of University of Science and Technology of China, Gerontology Institute of Anhui Province, Division of Life Sciences and Medicine
[2] Hefei HankeMab Biotechnology Limited,Anhui Province Key Laboratory of Gene Engineering Pharmaceutical, Biomedicine Technology Innovation Center of Hefei
[3] Anhui Provincial Key Laboratory of Tumor Immunotherapy and Nutrition Therapy,School of Life Sciences, Division of Life Sciences and Medicine
[4] Anhui Anke Biotechnology (Group) Co.,School of Health Service Management
[5] Ltd.,undefined
[6] University of Science and Technology of China,undefined
[7] Anhui Medical University,undefined
来源：
Cellular & Molecular Biology Letters | / 28卷
关键词：
Colorectal cancer; Cancer immunotherapy; 4-1BB/CD137; PD-1/PD-L1; Immune checkpoint inhibitor; Antitumor immunity;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] A COMPUTATIONAL SEMI-MECHANISTIC PHARMACOLOGY MODEL OF ATG101, A PD-L1/4-1BB BISPECIFIC ANTIBODY FOR TREATMENT OF SOLID TUMORS AND NHL
    Flowers, David
    Presler, Marc
    Subramanian, Kas
    Yuraszeck, Theresa
    Hui Yuwen
    Hou, Bing
    Hoenemann, Dirk
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A241 - A242
  • [32] Tumour inhibitory activity on pancreatic cancer by bispecific nanobody targeting PD-L1 and CXCR4
    Hao, Shuai
    Xu, Shuyi
    Li, Liangzhu
    Li, Yaxian
    Zhao, Meiqi
    Chen, Junsheng
    Zhu, Shunying
    Xie, Yueqing
    Jiang, Hua
    Zhu, Jianwei
    Wu, Mingyuan
    BMC CANCER, 2022, 22 (01)
  • [33] Tumour inhibitory activity on pancreatic cancer by bispecific nanobody targeting PD-L1 and CXCR4
    Shuai Hao
    Shuyi Xu
    Liangzhu Li
    Yaxian Li
    Meiqi Zhao
    Junsheng Chen
    Shunying Zhu
    Yueqing Xie
    Hua Jiang
    Jianwei Zhu
    Mingyuan Wu
    BMC Cancer, 22
  • [34] Radiolabelling and preclinical characterisation of [89Zr]Zr-Df-ATG-101 bispecific to PD-L1/4-1BB
    Cao, Zhipeng
    Wichmann, Christian Werner
    Burvenich, Ingrid Julienne Georgette
    Osellame, Laura Danielle
    Guo, Nancy
    Rigopoulos, Angela
    O'Keefe, Graeme Joseph
    Scott, Fiona Elizabeth
    Lorensuhewa, Nirmal
    Lynch, Kevin Patrick
    Scott, Andrew Mark
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 (11) : 3202 - 3214
  • [35] Assessment of target-mediated biodistribution of an 89Zr labeled PD-L1/4-1BB bispecific Mabcalin protein
    van Winkel, Claudia A.
    Fan, Xiaoyu
    Giesen, Danique
    Gauderat, Glenn
    Pattarini, Lucia
    Jaquin, Thomas
    Barakat, Anissa
    De La Bigne, Anne-Marie
    Richter, Marleen
    Andersen, Nicole
    Legrand, Julie
    Lelievre, Helene
    de Vries, Elisabeth G.
    Morales-Kastresana, Aizea
    Lub-de Hooge, Marjolijn N.
    CANCER RESEARCH, 2023, 83 (07)
  • [36] ABL503 (TJ-L14B), PD-L1X4-1BB BISPECIFIC ANTIBODY INDUCES SUPERIOR ANTI-TUMOR ACTIVITY BY PD-L1-DEPENDENT 4-1BB ACTIVATION WITH THE INCREASE OF 4-1BB+CD8+T CELLS IN TUMOR MICROENVIRONMENT
    Jung, Uijung
    Jeon, Jaehyoung
    Lee, Shinai
    Jin, Hyung-Seung
    Kim, Youngkwang
    Sung, Eunsil
    Kim, Hyunjoo
    Lim, Yangmi
    Won, Jonghwa
    Wang, Zhengyi
    Jiang, Wenqing
    Jung, Jaeho
    You, Gihoon
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A935 - A935
  • [37] Study of PRS-344/S095012 a PD-L1/4-1BB bispecific antibody-Anticalin®-fusion in patients with solid tumors.
    Jungels, Christiane
    Kotecki, Nuria
    Calvo, Emiliano
    Garralda, Elena
    Price, Timothy
    Zahn, Xiaojiang
    Abbas, Atif
    Mahnke, Lisa
    Rauschning, Winrich
    Morales-Kastresana, Aizea
    Pattarini, Lucia
    Bossenmaier, Birgit
    Scholer-Dahirel, Alix
    Demuth, Tim
    Legrande, Julie
    CANCER RESEARCH, 2022, 82 (12)
  • [38] A novel TIGIT and 4-1BB bispecific antibody, ABL112, exhibits potent in vitro and in vivo antitumor activity through dual immune modulation
    Son, Wonjun
    Lee, Yangsoon
    Park, Yelim
    Won, Jonghwa
    CANCER RESEARCH, 2024, 84 (06)
  • [39] A bispecific anti-PD-1 and PD-L1 antibody induces PD-1 cleavage and provides enhanced anti-tumor activity
    Albu, Diana I.
    Wolf, Benjamin J.
    Qin, Yan
    Wang, Xianzhe
    Ulumben, Amy Daniel
    Su, Mei
    Li, Vivian
    Ding, Eirene
    Gonzalo, Jose Angel
    Kong, Jason
    Jadhav, Ruturaj
    Kuklin, Nelly
    Visintin, Alberto
    Gong, Bing
    Schuetz, Thomas J.
    ONCOIMMUNOLOGY, 2024, 13 (01):
  • [40] BH3120, PD-L1 X 4-1BB bispecific antibody, plus PD-1 antagonist results in synergistic anti-tumor efficacy with excellent safety profile
    Wang, Jun
    Wang, Jing
    Liu, Yang
    Xu, Jiangcheng
    Liu, Jiawang
    Lee, Kyoungwoo
    CANCER RESEARCH, 2024, 84 (06)
12345